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Dr Robert J. Hye (San Diego, Calif). The past decade has seen
increasing recognition of the value of autogenous arteriovenous (AV)
fistulas in the hemodialysis population. AV fistulas are associated with
better patency, reduced risk of infection and less mortality as com-
pared to AV grafts and catheters. The Centers of Medicare and
Medicaid Services (CMS) Fistula First project and Kidney Disease
Outcomes Quality Initiative (KDOQI) guidelines have aggressively
promoted the use of AV fistulas, and the prevalence in the U.S. has
increased from33% in January of 2004 to 56% in June of 2010. Inmy
own organization, SouthernCalifornia Kaiser Permanente, our fistula
prevalence now exceeds 70% with some centers over 85%.nd actually, an increasing rate of maturation failure of between
5% and 45%. Anatomic and demographic variables such as blood
essel diameter, distensibility, age, gender, diabetes, and race have
ll been associated with an increased early failure rate. Biologic
rocesses that either inhibit vasodilatation or result in neointimal
yperplasia have also been implicated as causing fistulas to fail to
ature as expected.
Dr Lee and his colleagues have chosen to examine the biologic
spects of fistula failure and specifically the role of the metallopro-
eases (MMP)-2,MMP-9 and their tissue inhibitors in this process.
similar presentation from their group last year focused on tissueevels of these molecules in regard to fistula maturation while this
eport concentrates on serum levels, a potentially more clinically
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August 2011460 Lee et aluseful tool. These proteases have been studied in a variety of
vascular diseases, and their role is complex, involving variation in
the expression of the proteases themselves as well as their regula-
tory inhibitors and other bioactive molecules.
Expression of metalloproteases has been studied in many
vascular diseases and has been found to be increased in both
patients with aneurysmal disease and chronic kidney disease. Pa-
tients with diabetic nephropathy have been reported to have both
increased and decreased levels. Interestingly, one of the effects of
statins is a reduction in expression and activity of MMP-9. The
exact role of these proteins in vascular remodeling is not entirely
defined as yet.
The ideal biophysiologic response to creation of an arterio-
venous fistula that matures has been described as increased shear
stress in both the inflow artery and outflow vein causing an increase
in superoxide production. This combines with nitric oxide to form
peroxynitrite which upregulates MMP production, enhancing va-
sodilatation by fragmenting the internal elastic lamina of the
vessels. Occlusion of the fistula or maturation failure occurs when
this process is interrupted or does not proceed as described. Thus,
the authors’ premise is that measuring MMP-2 and 9 activity and
their regulatory inhibitors before, or at the time of fistula creation,
may allow us to predict maturation. The results presented today,
although in a very small sample size, show that measurement of
metalloprotease activity expressed as a ratio of levels of the protease
to its inhibitor, is increased at the time of surgery in patients who
go on to develop usable arteriovenous fistulas.
While the results are appealing, a number of important issues
are not addressed in the manuscript or presentation and are the
basis of my questions. It is not clear to me when and from where
the blood samples were obtained. Was it from the dissected artery
or vein? Wouldn’t it have been be more valid to obtain the sample
preoperatively from a peripheral vein?
Most of the literature in this area documents increased MMP
activity in response to fistula creation and not increased levels at
baseline. Is their any evidence that patients with increased basal
levels also have increased expression or activity in response to fistula
creation?
Demographics of the patient population were not provided;
specifically, how many women and diabetics were in each group as
these are factors also associated with differing rates of maturation.
MMP expression varies with severity of renal failure, were the
successful and failed fistula group comparable in the severity of
their kidney disease?
Although a minimum criteria for vessel size is provided, there
is no further description of the range or if the sizes were compara-
ble between the successful and the failed group. Can you tell us
about that?Finally, the criteria for a successful fistula is fairly soft, three
successful dialysis runs. Were these patients all dialyzed in the same
i
vnit? Did you examine flow rates or clearance in these patients? Do
ou have any longer-term data on outcome in these patients?
It would be very useful to have a biomarker such as MMP-2 or
9 to add to our armamentarium to be able to predict AV fistula
aturation. I look forward to Dr Lee’s further endeavors in this
rea. I would like to thank the society for the opportunity to discuss
his interesting and well-presented paper.
Dr Eugene S. Lee. Thank you, Dr Hye, for discussing the
anuscript and your insights. I will answer the questions in order
resented. Blood samples were obtained from the dissected artery
ntraoperatively. In conducting the study, I was concerned that
btaining blood from the vein would unintentionally injure the
ein and/or the endothelium, and I wanted to avoid this possibil-
ty. I am not sure whether blood from the peripheral vein vs the
rtery is more valid. In the next set of samples, I plan to draw both
rterial and venous blood samples and will assay for theMMP levels
o see a difference.
In terms of MMP activity in response to fistula creation is
nteresting, as the literature has confirmed that patients with wors-
ning renal functioning have increased MMP activity until they go
n to dialysis. Tomy knowledge, there is no information regarding
erum MMP activity in response to fistula creation.
I plan to include demographic information in the final manu-
cript. However, the patient population is mainly a veteran or VA
opulation and this group in the study is entirely men with a vast
ajority of patients who are diabetic. In fact, a large percentage of
hese patients have diabetes as the cause of their renal failure.
As forMMP expression, I will have to further evaluate the data
ith regards to the severity of renal failure. Many of the patients
eferred for AV access were in chronic kidney disease (CKD) stage
, but at the time of surgery, there were a proportion of patients
ho had proceeded to CKD stage 5 (on hemodialysis) at the time
f arteriovenous fistula (AVF) creation, making the analysis a
ixed analysis of various levels of MMP expression. Clearly, this is
weakness in the purity of the data, but it does add further
redence to the fact that varying renal dysfunction may not signif-
cantly impact the differences seen in patients who mature their
stulae vs those who do not.
In terms of vessel sizes, I do not have exact vessel sizes in each
roup for you today, but I recollect that the vessel sizes were
omparable between groups. I hope to have this information in the
nal manuscript.
Finally, with respect to the rather “soft criteria” for successful
stula creation, I have been struggling with this definition.
DOQI has plans to publish a more uniform standard of a “suc-
essful” AVF in 2011. When one reviews the literature, the defini-
ion is quite varied; hopefully, soon we can come to a consensus. As
or these patients being dialyzed in the same unit, the answer to this
s no. In terms of flow rates, we do have information regarding flow
olumes and vein diameters, which I will have to review.
